CaMKII as a Therapeutic Target in Cardiovascular Disease

Oscar E Reyes Gaido1, Lubika J Nkashama2, Kate L Schole1

  • 1Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;

Insights

Calcium/calmodulin-dependent protein kinase II (CaMKII) is implicated in diseases, but therapeutic inhibition is difficult. New strategies aim to target pathological CaMKII activity while preserving beneficial functions for effective treatments.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Calcium/calmodulin-dependent protein kinase II (CaMKII) is a critical signaling molecule implicated in numerous diseases, especially cardiovascular conditions.
  • Despite extensive preclinical evidence, CaMKII inhibitors have not yet translated into clinical practice.
  • Challenges include CaMKII's diverse isoforms/splice variants and its essential role in physiological processes like learning and memory.

Purpose of the Study:

  • To review the cellular and molecular biology of CaMKII.
  • To discuss CaMKII's role in both physiological and pathological signaling pathways.
  • To explore emerging therapeutic strategies for selectively targeting pathological CaMKII activity.

Main Methods:

  • Review of existing literature on CaMKII.
  • Analysis of CaMKII's function in various disease models.
  • Evaluation of novel therapeutic approaches, including small molecules, peptides, and nucleotides.

Main Results:

  • CaMKII plays a dual role, contributing to both disease pathogenesis and essential physiological functions.
  • Developing effective CaMKII inhibitors requires discriminating between harmful and beneficial activities.
  • Recent advancements in targeting strategies show promise for selective inhibition.

Conclusions:

  • Selective inhibition of pathological CaMKII activity is crucial for therapeutic success.
  • Emerging targeting strategies offer potential for developing CaMKII-based therapies.
  • Further research is needed to translate these findings into clinical applications for treating diseases.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
495
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
28
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
649
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
245